An interventional study of OPTIMIZER® Integra CCM-D System (Treatment Arm) in Heart Failure, Heart Failure With Reduced Ejection Fraction and Implantable Defibrillator User, sponsored by Impulse Dynamics. Active, not recruiting at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Impulse Dynamics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure by Impulse Dynamics — 4 open to participants now, 6 under way, none of them phase 3. Heart Failure · Impulse Dynamics.
Among the 11 studies in Heart Failure by Impulse Dynamics, this one is the only one that started in 2023, is one of 7 with no phase, and was the 8th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 11 studies in Heart Failure by Impulse Dynamics are open now, in 2 countries. Recruiting first, the newest first:
Impulse Dynamics · Sites in United States
Ages 18+
Impulse Dynamics · Sites in United States
Ages 18+
Impulse Dynamics · Sites in Italy
Ages 18+
Impulse Dynamics · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 300 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 160 across the 7 interventional studies, 2,410 across the 4 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Impulse Dynamics is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
1 of the studies in Heart Failure by Impulse Dynamics that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06580392Impulse DynamicsCCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Heart Failure by Impulse Dynamics, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).
Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals must meet all the following:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The subject is implanted with the CCM-D device.
Device: OPTIMIZER® Integra CCM-D System (Treatment Arm)
The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a "Cardiac Contractility Modulation - Defibrillator". All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years.
Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)
Evaluate the device effectiveness in converting induced VF at the time of implantation.
Time frame: Implant
Device-related Complications (Primary Safety Objective)
Evaluate device-related complications through 6-months (excluding lead-related complications).
Time frame: Implant to 6 months
Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)
Evaluate the incidence of inappropriate ICD shocks through the time when the last subject enrolled completes the 6-month visit.
Time frame: Implant to 6 months
Inappropriate Shock Rate out to 2-years
Evaluate the device effectiveness in converting spontaneous VT/VF through the time when the last subject enrolled completes the 6-month visit. Each subject will be followed for 2-years after implant to capture additional spontaneous episodes that may occur.
Time frame: Implant to 2 years
Charging non-compliance
Evaluate subject charging non-compliance defined as \>14 days between interval charging sessions, overall and frequency of non-compliance in the same subject.
Time frame: Implant to 2 years
Longitudinal levels of activity
Track longitudinal levels of activity weekly via OPTIhome (when available) and identification of trends.
Time frame: Implant to 2 years
Battery degradation and longevity
Assess battery degradation and longevity either remotely or during an in-person follow-up at 2 years (+/- 60 days) by recording QHR battery voltage as measured by the Integra CCM-D IPG. The measurement under nominal conditions is expected to be 2.85V or higher, consistent with a 20-year device longevity.
Time frame: Implant to 2 years
Compare worsening heart failure events pre- and post-implant
Track unscheduled cardiovascular-related healthcare encounters from 12 months prior to implant, if available, to 12 months post-implant
Time frame: 12 months prior to implant and 12 months post-implant
All-cause mortality
Assess all-cause mortality using Seattle Heart Failure Model (SHFM) and comorbidity burden as a predictive comparator at 1 year and 2 years post-implant
Time frame: 1 and 2 years post-implant
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Compare change in subject's perception of their heart failure symptoms, as measured by KCCQ, from baseline to 6 months.
Time frame: Baseline to 6-months
EQ-5D-5L
Compare change in subject's perception of their health status, as measured by the EQ-5D-5L, from baseline to 6 months.
Time frame: Baseline to 6-months
Six Minute Walk Distance (6MWD)
Compare change in functional capacity, as measured by 6MWD, from baseline to 6 months.
Time frame: Baseline to 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Dec 2025, 31 months.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 31 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Dec 2025, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Impulse Dynamics